Zymeworks Inc. (ZYME) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

being recorded. After the presentation, there will be an opportunity to ask questions. To ask a question, please press star, then one, one on your telephone keypad. I would now like to turn the conference over to Shurnal Inamdar, Senior Director of Investor Relations. Shurnal, please go ahead. Thank you, Ofresa, and good afternoon, everyone. Thank you for all joining our fourth quarter and year end 2024 results conference call. Before we begin, I would like to remind you that we'll be making a number of forward-looking statements during this call, including, without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary. Forward-looking statements are based upon our current expectations and various assumptions and are subject to the usual risks and uncertainties associated with companies in our industry and at our stage of development. For discussion of these risks and uncertainties, we refer you to our latest SEC filings as found on our website and as far as the SEC. In a moment, I will hand over to Leonie Paterson, our Executive Vice President and Chief Business and Financial Officer. Leonie will be discussing recent corporate updates along with financial results for our fourth quarter and year ended 2024. Following this, Dr. Paul Moore, our Chief Scientific Officer, will talk about key highlights from our fourth quarter, including our expanded focus on autoimmune and inflammatory diseases, as well as hematological oncology. At the end of the call, Leonie, Paul, and Ken Galbraith, our chair and CEO, will be available for Q&A. As a reminder, the audio and slides from this call will be available on the Zymox website later today. I will now hand the call over to Leonie. Over to you. Thank you, Chanel, and thank you a...